Related Experiment Video

Updated: Aug 16, 2026

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

ACOG Committee Opinion number 314, September 2005. Meningococcal vaccination for adolescents

    Obstetrics and Gynecology
    |September 2, 2005
    PubMed

    Insights

    Meningococcal conjugate vaccine (MCV4) is now recommended for preadolescents and adolescents to reduce meningococcal disease. Vaccination is advised before high school entry (around 15 years) and for college freshmen.

    Area of Science:

    • Public Health
    • Immunology
    • Vaccinology

    Background:

    • Meningococcal disease affects 1,400-2,800 individuals annually in the U.S.
    • Adolescents and young adults are at increased risk.
    • Current vaccination strategies aim to reduce disease incidence in these age groups.

    Purpose of the Study:

    • To outline updated recommendations for meningococcal conjugate vaccine (MCV4) administration.
    • To emphasize the importance of routine vaccination for disease prevention.
    • To inform healthcare providers about current guidelines.

    Main Methods:

    • Review of recommendations from the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC).
    • Inclusion of guidelines from the American College of Obstetricians and Gynecologists.
    • Focus on vaccination schedules for preadolescents, adolescents, and young adults.

    Main Results:

    • Routine vaccination of preadolescents with MCV4 is recommended.
    • Adolescents unvaccinated by age 15 should receive MCV4 before high school entry.
    • College freshmen living in dormitories are a key target group for vaccination.

    Conclusions:

    • Widespread adoption of MCV4 vaccination is crucial for reducing meningococcal disease burden.
    • Healthcare providers should actively promote and administer MCV4 to eligible individuals.
    • Awareness of meningococcal disease symptoms and vaccination benefits is essential.

    More Related Videos

    Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery10:03

    Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

    Published on: November 5, 2019

    Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development12:53

    Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

    Published on: March 16, 2022

    Related Concept Videos

    Cryptococcal Meningitis01:27

    Cryptococcal Meningitis

    Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
    Vaccinations01:51

    Vaccinations

    Overview
    Bacterial Meningitis I: Introduction01:22

    Bacterial Meningitis I: Introduction

    Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
    Bacterial Meningitis01:24

    Bacterial Meningitis

    Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
    Bacterial Meningitis II: Pathophysiology01:26

    Bacterial Meningitis II: Pathophysiology

    Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
    Viral Meningitis01:18

    Viral Meningitis

    Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...